İsmail HASIRCI, Mine ADAŞ, Ahu KEMİK SARBAY, Özgür KEMİK, Sevim PURİSA, Sefa TÜZÜN, Ahmet Cumhur DÜLGER

Transforming growth factor beta-1 in human colorectal cancer patients

Amaç: Kolorektal kanserli hastalar, cerrahi, radyoterapi ve kemoterapi ile tedavi edilirler. Transforming büyüme faktörü beta-1 (TGF-β1), hem tümörün büyümesini inhibe eder, hem de tümör progresyonunu sağlar. Bu çalışmanın amacı, kolorektal kanserli hastalarda, TGF-β1 düzeylerini ölçmek ve bu hastaların klinikopatolojik değişiklikler ile ilişkisi olduğunu vurgulamaktır. Metod: Cerrahi uygulanan 100 kolorektal kanserli hasta incelemeye alındı. Hastaların kan örnekleri, cerrahi müdahale sırasında alındı ve sonrasında total TGF-β1 ve aktif TGF-β1 düzeyleri için enzim bağlı immunosorbent ölçüm (ELISA) yapıldı. Bulgular: Total ve aktif TGF-β1 düzeyleri, kolorektal kanserli hastalarda kontrollere göre yüksek bulundu (p

Kolorektal kanserli hastalarda transforming büyüme faktörü

Aim: Colorectal cancer patients are treated with surgery and sometimes radiotherapy and chemotherapy. Transforming growth factor beta-1 (TGF-β1) acts both as an inhibitor of tumor growth and as a promoter of tumor progression. The aim of this study was to determine the levels of TGF-β1 in plasma in colorectal cancer patients and relate these to the effect of clinicopathological variables. Method: One hundred patients scheduled for colorectal cancer surgery were included. Blood samples were taken during surgery and later assayed with enzyme linked immunsorbent assay for total TGF-β1 and active TGF-β1. Result: Total and active TGF-β1 was higher in tumor samples compared to controls (p

PDF

___

1. Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor beta. Growth factors 1993; 8: 1-9.
2. Massague J. TGFβ signaling: receptors, transducers, and mad proteins. Cell 1996; 85: 947-950.
3. Geiser AG, Busam KJ, Kim SJ, et al. regulation of the transforming growth factor-beta1 and beta3 promotes by transcription factor Sp1. Gene 1993; 129: 223-228.
4. Grande JP. Role of the transforming growth factor beta in tissue injury and repair. PSEBM 1997; 214: 27-40.
5. Wineselt MP, Ramsey GW, Barnard JA. Type II TGF-beta receptor expression in intestinal cell lines and intestinal tract. Carcinogenesis 1996; 67: 573-579.
6. Landström M, Eklöv S, Colosetti P, et al. Estrogen induces apoptosis in a rat prostatic adenocarcinoma. Association with an increased expression of TGF beta1 and its type-1 and type-II receptors. Int J cancer 1996; 67: 573-579.
7. Sun LZ, Wu G, Wilson JKV, et al. Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem 1994; 269: 26449-26455.
8. Kim WS, Park C, Jung YS, et al. Reduced transforming growth factor beta type II receptor expression in adenocarcinoma of the lung. Anticancer Res 1999, 19. 301-306.
9. Lawrance DA. Latent-TGF-beta: an overview. Mol Cell Biochem 2001;219:163-70.
10. Hill Rp, Rodemann HP, Hendry JH, Roberts SA, Anscher MS. Normal tissue radiobiology: from the laboratory to the clinic. Int J Radiat Oncol Biol Phys 2001;49:353-65.
11. Wu SP, Theodorescu D, Kerbel RS, Willson JK, Mulder KM, Humphrey LE, Brattain MG. TGF-beta 1 is an autocrinenegative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J Cell Biol 1992;116:187-96.
12. Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S, Cohen A. High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev 1995; 4: 549-554.
13. Angenete E, Langenskiöld M, Palmgren I, Falk P, Öresland T, Ivarsson ML. Transforming growth factor beta-1 in rectal tumor, mucosa and plasma in relation to radiotherapy and clinical outcome in rectal cancer patients. Int J Colorectal Dis 2007;22:1331-8.
14. Narai S, Watanabe M, Hasegawa H, Nishibori H, Endo T, Kubota T, Kitajima M. Significance of transforming growth factor beta 1 as a new tumor marker for colorectal cancer. Int J Cancer 2002;97:508-11.
15. Tsamandas AC, Kardamakis D, Ravazoula P, Zolota V, Salakou S, et al. The potential role of TGF beta1, TGF beta2 and TGF beta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival. Strahlenther Onkol 2004;180:201-8.
16. Kushiyama Y, Fukuda R, Suetsugu H, et al. Site-dependent production of transforming growth factor beta-1 in colonic mucosa: its possible role in tumorigenesis of the colon. J Lab Clin Med 2000; 136: 201-8.
17. Tsushima H, Kawata S, tamura S, Ito N, Shirai Y, Kiso S, Imai Y, et al. High levels of transforming growth factor beta1 in patients with colorectal cancer: association with disease progression. Gastroenterology 1996; 110: 375-82.
18. Shim KS, Kim KH, Han WS, Park EB. Elevated serum levels of transforming growth factor beta1 in patients with colorectal cancer: its association with tumor progression and its significant decrease after curative surgical resection. Cancer 1999; 85: 554-61.